- $85.90bn
- $101.52bn
- $25.51bn
- 34
- 27
- 52
- 31
Annual cashflow statement for Medline, fiscal year end - December 31st, millions except per share.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | — | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | |
| Standards: | — | USG | USG |
| Status: | fx Preliminary | Final | Final |
| Net Income/Starting Line | — | 234 | 1,200 |
| Depreciation | |||
| Deferred Taxes | |||
| Non-Cash Items | — | 325 | 291 |
| Unusual Items | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | — | 199 | -675 |
| Change in Accounts Receivable | |||
| Change in Inventories | |||
| Change in Other Assets | |||
| Change in Accounts Payable | |||
| Change in Accrued Expenses | |||
| Change in Other Liabilities | |||
| Cash from Operating Activities | — | 1,685 | 1,769 |
| Capital Expenditures | — | -275 | -354 |
| Purchase of Fixed Assets | |||
| Other Investing Cash Flow Items | — | -37 | -1,139 |
| Acquisition of Business | |||
| Sale/Maturity of Investment | |||
| Purchase of Investments | |||
| Other Investing Cash Flow | |||
| Cash from Investing Activities | — | -312 | -1,493 |
| Financing Cash Flow Items | — | -114 | -1,530 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | — | -191 | -1,613 |
| Foreign Exchange Effects | |||
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | — | 1,186 | -1,335 |